Navigation Links
RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
Date:7/8/2011

NATICK, Mass., July 8, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce the opening of another state of the art facility in Greece for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

The Company's treatment for congestive heart failure is administered at the Metropolitan Hospital in Athens, which is part of the PERSEUS Heath Care Group.  Greece is a convenient location for patients living in Europe and offers patients an additional location where the company's autologous stem cell treatments are permitted.

About RegenoCELL Therapeutics, Inc.

RegenoCELL Therapeutics, Inc. is a stem cell therapy company using adult stem cells for autologous treatment of patients.  The Company plans to obtain regulatory approval in the United States and the European Community to market its stem cell treatments.  Through its wholly owned foreign subsidiaries, the company is marketing its stem cell treatments for transplantation in jurisdictions where autologous therapy is permitted.

Cardiac Disease

There are therapies to treat congestive heart failure.  But there comes a treatment point when the only option may be a heart transplant.  Over 25,000 people are on the transplant lists but fewer than 2,500 receive one.  The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.  

Peripheral Artery Disease

The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.

Since 2005, the company's stem cell therapy has successfully treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live.  A half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel.  There the patient's stem cells are extracted and grown from tens of thousands into many millions.  The stem cells are primed for angiogenesis or blood vessel formation.  The patient then travels to a jurisdiction where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catherization laboratory in a procedure similar to angioplasty.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements.  These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii) our inability to predict the extent of our future losses or if or when we will become  profitable; (viii) our ability to protect our intellectual property rights; and, (ix) intense competition.  The Company is also subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on 'From 10-Q for the quarter ended March 31, 2011.

Contact: James Mongiardo, 508-647-4065, jmongiardo@regenocell.com


'/>"/>
SOURCE RegenoCELL Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... 2017  Agriculture technology company Cool Planet has closed ... conversion to commercialize its Cool Terra and Cool Fauna ... products that are simultaneously profitable as well as sustainable ... 18 months. This latest round of funding was led ... The company,s primary product, Cool Terra, can ...
(Date:3/22/2017)... ... 22, 2017 , ... Researchers face a fundamental challenge as ... full-size tissues, bones, even whole organs to implant in people to treat disease ... into the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t ...
Breaking Biology Technology:
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
Breaking Biology News(10 mins):